Pembrolizumab,Lenvatinib,Sunitinib
Merck,Pfizer,eisai
['improve ', 'sunitinib', 'rcc,(-irccs),(-srcc),(-urcc)', 'lenva', 'pembro']
#esmo22 clear ph3 trial update: lenvatinib+pembrolizumab continues to significantly improve pfs vs. sunitinib in mrcc #kidneycancer 23 vs 9.3 months. 
Medical Oncologist. Editor-in-chief: @ASCO Daily News; Presidential Endowed Chair, @HuntsmanCancer (NCI-CCC) @UUtah, FCOI https://t.co/qcdl195o3E